Saturday 17 October 2026
Export VALN’s income statement to Excel — free account
Valneva SE Sponsored ADR
VALN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 17.3%, EPS fell 222.1%, free cash flow fell 56.1% and total debt rose 12.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
5.61
0.30
−5.08%
Follow VALN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | 2 | 0 | 5 | 4 | — | — | — | — |
P/E ratio |
22.99 | 18.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(0.49) | (0.12) | (0.15) | 0.61 | 2.22 | — | — | — | — | — |
P/S ratio |
3.95 | 1.97 | 2.98 | 2.55 | 22.34 | 10.28 | 10.28 | 10.28 | 10.28 | 10.28 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 16.45 | 4.16 | 4.16 | 4.16 | 4.16 | 4.16 |
Altman Z″-Score (non-manufacturers) |
(3.49) | (0.40) | (2.50) | (0.71) | 0.58 | 0.10 | 0.74 | 1.66 | — | (0.34) |
Beneish M-Score |
(3.28) | (2.16) | 0.03 | (0.39) | (1.49) | (4.89) | (1.73) | — | — | — |
P/Operating CF |
(20.45) | (3.63) | (4.77) | (15.20) | (55.39) | 21.26 | 21.26 | 21.26 | 21.26 | 21.26 |
P/B ratio |
3.86 | 1.28 | 4.14 | 4.03 | 35.66 | 19.32 | 19.32 | 19.32 | 19.32 | 19.32 |
Price to Tangible BV |
4.56 | 1.51 | 4.98 | 4.64 | 64.44 | 58.80 | 58.80 | 58.80 | 58.80 | 58.80 |
EV/Sales |
4.12 | 2.08 | 2.84 | 2.16 | 20.57 | 8.44 | 8.44 | 8.44 | 8.44 | 8.44 |
EV/EBITDA |
30.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(5.44) | (1.06) | (2.38) | (3.07) | 15.14 | 3.41 | 3.41 | 3.41 | 3.41 | 3.41 |
EV/FCF |
(4.45) | (0.96) | (2.12) | (2.43) | 15.14 | 3.41 | 3.41 | 3.41 | 3.41 | 3.41 |
Quick Ratio |
1.47 | 1.78 | 1.06 | 1.13 | 1.06 | 1.27 | 2.14 | 2.17 | 1.48 | 1.52 |
Current Ratio |
2.38 | 2.61 | 1.65 | 1.53 | 1.59 | 1.75 | 3.13 | 2.93 | 2.22 | 2.34 |
Net Debt/EBITDA |
(1.15) | 0.58 | (0.79) | 2.06 | 6.13 | 3.33 | 16.81 | (2.69) | 5.31 | 12.75 |
Debt/Assets |
44.92% | 37.47% | 38.44% | 15.90% | 7.08% | 11.88% | 31.08% | 24.02% | 0.00% | 39.88% |
Debt/Equity |
1.69 | 1.03 | 1.38 | 0.45 | 0.34 | 0.69 | 0.63 | 0.40 | 0.77 | 0.82 |
Asset Turnover |
0.40 | 0.35 | 0.29 | 0.47 | 0.56 | 0.31 | 0.49 | 0.53 | 1.17 | 0.44 |
Operating CF/Net income |
0.46 | 5.49 | 2.00 | 1.71 | (1.05) | (2.14) | (1.78) | 3.77 | (0.69) | 0.02 |
Capex/Depreciation |
(0.20) | (0.83) | (0.81) | (1.39) | (6.52) | (1.98) | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(1.96) | 0.56 | (3.52) | (5.95) | (3.62) | (5.13) | (5.15) | 1.07 | (1.89) | (2.54) |
| (82.42%) | (7.91%) | (59.28%) | (69.66%) | (59.86%) | (61.22%) | (1.24%) | 2.72% | (12.75%) | (47.72%) | |
| (26.27%) | (2.55%) | (19.05%) | (18.62%) | (11.74%) | (17.92%) | (0.67%) | 1.52% | (12.70%) | (23.22%) | |
ROIC |
(29.19%) | 4.16% | (28.66%) | (243.03%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(46.32%) | (3.79%) | (42.23%) | (55.17%) | (21.44%) | (38.48%) | (1.11%) | 2.70% | (13.65%) | (53.84%) |
Average Days of Receivables |
58.12 | 75.77 | 98.89 | 24.16 | 46.15 | 63.63 | 69.50 | 36.36 | 61.09 | 65.63 |
Research and Development Expense of Revenue |
48.84% | 43.72% | 38.96% | 29.04% | 49.78% | 76.55% | 29.15% | 22.37% | 21.04% | 24.62% |
Selling, General and Administrative Expense of Revenue |
42.76% | 56.08% | 62.81% | 15.94% | 20.47% | 41.52% | 33.39% | 33.50% | 31.54% | 32.84% |
Intangible Assets out of Total Assets |
0.06 | 0.05 | 0.06 | 0.05 | 0.04 | 0.08 | 0.15 | 0.19 | 0.00 | 0.29 |
Share Based Compensation of Revenue |
5.46% | 4.70% | 3.33% | (2.40%) | 4.17% | 5.74% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.05) | 0.02 | (0.06) | 0.01 | (0.04) | (0.10) | (0.10) | (0.10) | (0.10) | (0.10) |
Graham Number |
1.46 | 4.55 | 3.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
4.35% | 5.35% | (9.93%) | (12.27%) | (6.00%) | (5.75%) | (5.75%) | (5.75%) | (5.75%) | (5.75%) |
Free Cash Flow Yield |
(23.41%) | (109.75%) | (45.07%) | (34.73%) | 6.08% | 24.06% | 24.06% | 24.06% | 24.06% | 24.06% |
Revenue per Share |
2.35 | 2.52 | 2.40 | 6.59 | 8.44 | 2.78 | 3.09 | 3.23 | 2.31 | 2.44 |
Operating CF per Share |
(0.71) | (1.00) | (3.17) | (4.48) | 1.86 | 3.47 | 0.08 | 0.35 | 0.17 | (0.03) |
Capex per Share |
(0.06) | (0.24) | (0.22) | (0.53) | (2.26) | (0.49) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.77) | (1.24) | (3.39) | (5.01) | (0.39) | 2.98 | 0.08 | 0.35 | 0.17 | (0.03) |
Cash per Share |
1.48 | 2.50 | 1.97 | 5.28 | 8.40 | 5.15 | 1.58 | 2.33 | 0.84 | 1.09 |
Shareholders Equity per Share |
1.43 | 2.69 | 2.00 | 4.01 | 4.13 | 1.95 | 3.31 | 4.09 | 2.03 | 2.59 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.43 | 2.69 | 2.00 | 4.01 | 4.13 | 1.95 | 3.31 | 4.09 | 2.03 | 2.59 |
Free Cash Flow |
(64.77) | (90.35) | (234.80) | (289.38) | (19.25) | 135.12 | 3.49 | 14.16 | 9.54 | (1.20) |
Working Capital |
146.18 | 199.57 | 112.52 | 155.16 | 256.56 | 151.42 | 98.72 | 95.43 | 55.15 | 55.06 |
Capital Expenditures |
(4.92) | (17.62) | (15.37) | (30.89) | (110.23) | (22.21) | (12.23) | (3.64) | (4.87) | (3.88) |
Net Current Asset Value |
(79.34) | (21.39) | (74.67) | 24.35 | (72.10) | (72.32) | (11.04) | 33.71 | (15.93) | (16.46) |
EV/EBIT |
24.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.10 | 0.09 | 0.08 | 0.27 | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
23.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.18 | 0.14 | 0.13 | 0.19 | 0.11 | 0.28 | 0.12 | 0.18 | 0.29 | 0.29 |
Cash ROIC |
(14.49%) | (15.55%) | (50.31%) | (45.17%) | (2.83%) | 35.29% | 1.09% | 4.36% | 3.92% | (0.51%) |
Accounts Receivable Turnover |
5.68 | 4.41 | 4.74 | 9.85 | 11.12 | 5.15 | 7.10 | 7.60 | 6.50 | 5.07 |
Accounts Payable Turnover |
3.66 | 2.47 | 2.38 | 5.50 | 3.65 | 2.42 | 5.96 | 6.49 | 14.57 | 12.09 |
Inventory Turnover |
2.11 | 2.01 | 2.57 | 3.72 | 2.50 | 2.08 | 2.22 | 2.18 | 2.74 | 2.28 |
Average Days of Payables |
83.60 | 131.58 | 160.30 | 46.68 | 132.31 | 243.41 | 59.47 | 70.32 | 35.18 | 17.99 |
Days of Inventory on Hand |
171.13 | 198.78 | 160.89 | 39.49 | 241.04 | 181.03 | 172.82 | 174.18 | 133.35 | 159.94 |
Average Receivables |
34.78 | 41.58 | 35.13 | 38.63 | 37.02 | 24.48 | 19.97 | 17.09 | 19.52 | 19.52 |
Average Payables |
33.10 | 43.19 | 45.83 | 62.15 | 60.98 | 25.66 | 10.26 | 8.44 | 4.51 | 4.51 |
Average Inventory |
57.45 | 53.10 | 42.56 | 91.90 | 88.79 | 29.86 | 27.54 | 25.07 | 23.95 | 23.95 |
Average Assets |
496.16 | 519.50 | 576.29 | 810.83 | 740.04 | 410.55 | 291.85 | 246.72 | 108.89 | 222.95 |
Average Common Equity |
158.13 | 167.47 | 185.19 | 216.70 | 145.13 | 120.15 | 158.22 | 138.12 | 108.48 | 108.48 |
Columns are period end dates